H3K27(Me3) (15-34)

Product Name: H3K27(Me3) (15-34)

Purity: 95%

Molar Mass: 2023.4

Chemical Formula: C87H157N30O25

Storage: Store at -20 degree Celsius

Sequence: APRKQLATKAARKSAPATGG

Application: H3K27(Me3) (15-34) is a synthetic peptide corresponding to amino acids 15-34 of histone H3, trimethylated at the lysine 27 (K27) residue. This post-translational modification is a key epigenetic mark associated with transcriptional repression and the formation of heterochromatin. The trimethylation of H3K27 is mediated by the Polycomb Repressive Complex 2 (PRC2) and plays a vital role in gene silencing, developmental processes, and the maintenance of stem cell identity. H3K27(Me3) (15-34) is widely utilized in epigenetic research to study chromatin dynamics, gene regulation, and the mechanisms underlying various diseases, including cancer. Its application is crucial for developing targeted epigenetic therapies.

Current Research:

H3K27(Me3) (15-34) is a synthetic peptide encompassing amino acids 15 to 34 of histone H3, with trimethylation at lysine 27 (K27). This specific post-translational modification is a hallmark of transcriptional repression and plays a pivotal role in the regulation of gene expression.
Role of H3K27 Trimethylation in Gene Regulation
The trimethylation of H3K27 is catalyzed by the Polycomb Repressive Complex 2 (PRC2), a multiprotein complex that facilitates the addition of methyl groups to lysine residues on histone tails. This modification serves as a repressive chromatin mark, leading to the condensation of chromatin structure and subsequent gene silencing. H3K27me3 is frequently found in heterochromatin regions and is linked with the suppression of gene activity.
Applications of H3K27(Me3) (15-34) in Research
The H3K27(Me3) (15-34) peptide is utilized as a substrate in studies investigating the activity of histone methyltransferases and demethylases. By providing a defined sequence with a specific methylation state, researchers can examine how these enzymes interact with methylated histone tails, thereby enhancing our understanding of epigenetic regulation mechanisms.
Implications in Disease and Therapeutics
Aberrant methylation at H3K27 is implicated in various diseases, including cancer. Overexpression of PRC2 components can lead to excessive H3K27 methylation, resulting in the silencing of tumor suppressor genes. Conversely, loss of H3K27 methylation due to mutations in demethylases can activate oncogenes. Consequently, targeting the enzymes that modulate H3K27 methylation is being explored as a therapeutic strategy in oncology.
Conclusion
The H3K27(Me3) (15-34) peptide serves as a valuable tool in epigenetic research, facilitating the study of histone modifications and their impact on gene expression. Understanding the dynamics of H3K27 trimethylation is essential for developing novel therapeutic approaches for diseases associated with epigenetic dysregulation.

Reference: Breton, A., Le Bourhis, D., Audouard, C., Vignon, X., & Lelievre, J. M. (2010). Nuclear profiles of H3 histones trimethylated on Lys27 in bovine (Bos taurus) embryos obtained after in vitro fertilization or somatic cell nuclear transfer. Journal of Reproduction and Development, 56(4), 379-388.